Definium Therapeutics (NASDAQ:DFTX) used its full-year 2025 earnings call to highlight impending late-stage clinical ...
I am pleased to share Pacira BioSciences, Inc.'s fourth quarter and full year 2025 results and to reflect on what was truly a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results